Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma.

Badros AZ, Ma N, Rapoport AP, Lederer E, Lesokhin AM.

Blood Adv. 2019 Jun 11;3(11):1658-1660. doi: 10.1182/bloodadvances.2019000191. No abstract available.

2.

Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample Database.

Liu Y, Han H, Shah G, Giralt S, Ola Landgren C, He J, Lesokhin AM.

Biol Blood Marrow Transplant. 2019 Jan;25(1):41-46. doi: 10.1016/j.bbmt.2018.08.030. Epub 2018 Sep 6.

PMID:
30195073
3.

Clinical Development of PD-1 Blockade in Hematologic Malignancies.

Pianko MJ, Goldberg AD, Lesokhin AM.

Cancer J. 2018 Jan/Feb;24(1):31-35. doi: 10.1097/PPO.0000000000000297. Review.

4.

Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.

Lendvai N, Tsakos I, Devlin SM, Schaffer WL, Hassoun H, Lesokhin AM, Landau H, Korde N, Mailankody S, Smith E, Chung DJ, Koehne G, Shah GL, Alexander A, Patel M, Ballagi A, Grundberg I, Giralt SA, Landgren O.

Leuk Lymphoma. 2018 Aug;59(8):1981-1985. doi: 10.1080/10428194.2017.1403020. Epub 2018 Jan 8. No abstract available.

PMID:
29308691
5.

Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.

Palazzo M, Shah GL, Copelan O, Seier K, Devlin SM, Maloy M, Kenny S, Hassoun H, Korde NS, Lendvai N, Lesokhin AM, Mailankody S, Chung DJ, Koehne G, Landgren CO, Landau H, Giralt SA, Perales MA.

Biol Blood Marrow Transplant. 2018 Apr;24(4):871-876. doi: 10.1016/j.bbmt.2017.12.795. Epub 2017 Dec 27.

6.

Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.

Pianko MJ, Moskowitz AJ, Lesokhin AM.

Clin Cancer Res. 2018 Mar 1;24(5):1002-1010. doi: 10.1158/1078-0432.CCR-17-0539. Epub 2017 Sep 12. Review.

7.

Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.

Pianko MJ, Funt SA, Page DB, Cattry D, Scott EC, Ansell SM, Borrello IM, Gutierrez M, Lendvai N, Hassoun H, Landgren CO, Lesokhin AM.

Leuk Lymphoma. 2018 Jan;59(1):221-224. doi: 10.1080/10428194.2017.1320713. Epub 2017 May 30. No abstract available.

8.

Immune checkpoint blockade for hematologic malignancies: a review.

Pianko MJ, Liu Y, Bagchi S, Lesokhin AM.

Stem Cell Investig. 2017 Apr 19;4:32. doi: 10.21037/sci.2017.03.04. eCollection 2017. Review.

9.

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.

Martin T, Baz R, Benson DM, Lendvai N, Wolf J, Munster P, Lesokhin AM, Wack C, Charpentier E, Campana F, Vij R.

Blood. 2017 Jun 22;129(25):3294-3303. doi: 10.1182/blood-2016-09-740787. Epub 2017 May 8.

10.

Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance.

Hassoun H, Roshal M, Sabari J, Nguyen J, Gao Q, Devlin SM, Landau H, Lendvai N, Chung DJ, Lesokhin AM, Korde N, Mailankody S, Dogan A, Giralt SA, Landgren CO.

Leuk Lymphoma. 2017 Dec;58(12):2962-2965. doi: 10.1080/10428194.2017.1312382. Epub 2017 May 9. No abstract available.

PMID:
28482750
11.

Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.

Shah GL, Landau H, Londono D, Devlin SM, Kosuri S, Lesokhin AM, Lendvai N, Hassoun H, Chung DJ, Koehne G, Jhanwar SC, Landgren O, Levine R, Giralt SA.

Leuk Lymphoma. 2017 Aug;58(8):1823-1831. doi: 10.1080/10428194.2016.1260126. Epub 2017 Jan 12.

12.

Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.

Murata K, McCash SI, Carroll B, Lesokhin AM, Hassoun H, Lendvai N, Korde NS, Mailankody S, Landau HJ, Koehne G, Chung DJ, Giralt SA, Ramanathan LV, Landgren O.

Clin Biochem. 2018 Jan;51:66-71. doi: 10.1016/j.clinbiochem.2016.09.015. Epub 2016 Sep 21.

13.

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD.

J Clin Oncol. 2017 Mar;35(7):709-717. doi: 10.1200/JCO.2016.68.2005. Epub 2016 Sep 30. Erratum in: J Clin Oncol. 2017 Aug 1;35(22):2590.

14.

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J.

J Clin Oncol. 2016 Aug 10;34(23):2698-704. doi: 10.1200/JCO.2015.65.9789. Epub 2016 Jun 6.

15.

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.

Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, Motzer RJ, Wu S, Busam KJ, Wolchok JD, Lacouture ME.

Eur J Cancer. 2016 Jun;60:12-25. doi: 10.1016/j.ejca.2016.02.010. Epub 2016 Apr 1. Review.

16.

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.

Lendvai N, Yee AJ, Tsakos I, Alexander A, Devlin SM, Hassoun H, Korde N, Lesokhin AM, Landau H, Mailankody S, Koehne G, Chung DJ, Landgren O, Raje NS, Giralt S.

Blood. 2016 May 12;127(19):2355-6. doi: 10.1182/blood-2016-01-694786. Epub 2016 Mar 28. No abstract available.

17.

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.

Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, Postow MA, Weinstein A, Lucas AS, Ciccolini KT, Quigley EA, Lesokhin AM, Paik PK, Chaft JE, Segal NH, D'Angelo SP, Dickson MA, Wolchok JD, Lacouture ME.

Cancer Immunol Res. 2016 May;4(5):383-9. doi: 10.1158/2326-6066.CIR-15-0123. Epub 2016 Feb 29.

18.

Transjugular Liver Biopsy in a Multiple Myeloma Patient with Hepatomegaly, Portal Hypertension and "Miliary" Liver Lesions: A Case Report.

Gonzalez-Aguirre AJ, Lin O, Cho C, Lesokhin AM, Maybody M.

J Gastrointest Dig Syst. 2016 Feb;6(1). pii: 390. doi: 10.4172/2161-069X.1000390. Epub 2016 Feb 10.

19.

T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy.

Chung DJ, Pronschinske KB, Shyer JA, Sharma S, Leung S, Curran SA, Lesokhin AM, Devlin SM, Giralt SA, Young JW.

Cancer Immunol Res. 2016 Jan;4(1):61-71. doi: 10.1158/2326-6066.CIR-15-0055. Epub 2015 Oct 13.

20.

CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.

Smith E, Devlin SM, Kosuri S, Orlando E, Landau H, Lesokhin AM, Chung DJ, Hassoun H, Lendvai N, Landgren O, Giralt S, Chari A, Jagannath S, Koehne G.

Biol Blood Marrow Transplant. 2016 Feb;22(2):258-267. doi: 10.1016/j.bbmt.2015.08.025. Epub 2015 Aug 30.

21.

On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.

Lesokhin AM, Callahan MK, Postow MA, Wolchok JD.

Sci Transl Med. 2015 Mar 25;7(280):280sr1. doi: 10.1126/scitranslmed.3010274. Review.

PMID:
25810313
22.

Minimal residual disease in multiple myeloma: bringing the bench to the bedside.

Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M, Landgren O.

Nat Rev Clin Oncol. 2015 May;12(5):286-95. doi: 10.1038/nrclinonc.2014.239. Epub 2015 Jan 27. Review.

PMID:
25622976
23.

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P.

N Engl J Med. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6.

24.

Harnessing the immune system for cancer therapy.

Smith EL, Zamarin D, Lesokhin AM.

Curr Opin Oncol. 2014 Nov;26(6):600-7. doi: 10.1097/CCO.0000000000000128. Review.

PMID:
25250678
25.

A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.

Lendvai N, Hilden P, Devlin S, Landau H, Hassoun H, Lesokhin AM, Tsakos I, Redling K, Koehne G, Chung DJ, Schaffer WL, Giralt SA.

Blood. 2014 Aug 7;124(6):899-906. doi: 10.1182/blood-2014-02-556308. Epub 2014 Jun 24.

26.

Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes.

Kitano S, Postow MA, Ziegler CG, Kuk D, Panageas KS, Cortez C, Rasalan T, Adamow M, Yuan J, Wong P, Altan-Bonnet G, Wolchok JD, Lesokhin AM.

Cancer Immunol Res. 2014 Aug;2(8):812-21. doi: 10.1158/2326-6066.CIR-14-0013. Epub 2014 May 20.

27.

Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma.

Postow MA, Yuan J, Kitano S, Lesokhin AM, Wolchok JD.

Methods Mol Biol. 2014;1102:83-95. doi: 10.1007/978-1-62703-727-3_6.

PMID:
24258975
28.

Nivolumab plus ipilimumab in advanced melanoma.

Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M.

N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.

29.

Myeloid-derived suppressor sells and the efficacy of CD8+ T-cell immunotherapy.

Lesokhin AM, Merghoub T, Wolchok JD.

Oncoimmunology. 2013 Feb 1;2(2):e22764.

30.

Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype.

Hirschhorn-Cymerman D, Budhu S, Kitano S, Liu C, Zhao F, Zhong H, Lesokhin AM, Avogadri-Connors F, Yuan J, Li Y, Houghton AN, Merghoub T, Wolchok JD.

J Exp Med. 2012 Oct 22;209(11):2113-26. doi: 10.1084/jem.20120532. Epub 2012 Sep 24.

31.

Immunologic correlates of the abscopal effect in a patient with melanoma.

Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD.

N Engl J Med. 2012 Mar 8;366(10):925-31. doi: 10.1056/NEJMoa1112824.

32.

Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.

Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, Rizzuto GA, Lazarus JJ, Pamer EG, Houghton AN, Merghoub T, Wolchok JD.

Cancer Res. 2012 Feb 15;72(4):876-86. doi: 10.1158/0008-5472.CAN-11-1792. Epub 2011 Dec 15.

33.

Hiding the road signs that lead to tumor immunity.

Schaer DA, Lesokhin AM, Wolchok JD.

J Exp Med. 2011 Sep 26;208(10):1937-40. doi: 10.1084/jem.20111856. Review.

34.

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs.

Nakahara T, Uchi H, Lesokhin AM, Avogadri F, Rizzuto GA, Hirschhorn-Cymerman D, Panageas KS, Merghoub T, Wolchok JD, Houghton AN.

Blood. 2010 Jun 3;115(22):4384-92. doi: 10.1182/blood-2009-11-251231. Epub 2010 Feb 12.

35.

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.

Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, Cohen AD, Avogadri F, Lesokhin AM, Weinberg AD, Wolchok JD, Houghton AN.

J Exp Med. 2009 May 11;206(5):1103-16. doi: 10.1084/jem.20082205. Epub 2009 May 4.

36.

Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response.

Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, Zhong H, Panageas KS, Perales MA, Altan-Bonnet G, Wolchok JD, Houghton AN.

J Exp Med. 2009 Apr 13;206(4):849-66. doi: 10.1084/jem.20081382. Epub 2009 Mar 30.

37.

Inhibition of chemokine expression by adenovirus early region three (E3) genes.

Lesokhin AM, Delgado-Lopez F, Horwitz MS.

J Virol. 2002 Aug;76(16):8236-43.

38.

Supplemental Content

Loading ...
Support Center